The BLZF1 Knockout HAP1 Polyclonal Cells product comprises a population of HAP1 cells with targeted disruption of the BLZF1 gene via CRISPR/Cas9-mediated gene editing. This polyclonal knockout cell population is generated without single-cell cloning, resulting in a heterogeneous pool of cells harboring diverse loss-of-function alleles at the BLZF1 locus. The cells are intended for use in functional genomics studies, enabling researchers to interrogate the biological roles of this basic leucine zipper transcription factor in a genetically controlled background. The polyclonal format provides a robust model for pooled screening and population-level assays, avoiding clonal artifacts while maintaining efficient gene disruption across the culture.
The host HAP1 cell line is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia line, exhibiting a male karyotype with haploidy for most chromosomes except disomy of chromosome 8. This unique genetic configuration renders HAP1 cells particularly powerful for recessive mutation studies and haploid genetic screens, as a single disruptive edit is sufficient to produce a functional knockout phenotype. HAP1 cells retain key signaling pathways relevant to cancer biology, making them an ideal chassis for investigating tumor suppressor and oncogene functions. Their adherent growth and ease of culture further facilitate high-throughput experimental workflows.
At the molecular level, BLZF1 encodes a basic leucine zipper transcription factor that integrates signals from growth factor stimulation and intracellular kinase cascades. Its activity is regulated by MAPK pathway components such as ERK1/2 and JNK, which phosphorylate and control its dimerization and nuclear translocation. Canonical Wnt ligands promote ??-catenin stabilization, enabling collaborative regulation of target genes. BLZF1 forms transcriptional complexes with interacting partners including JUN, FOS, and SMAD family proteins, thereby modulating the expression of downstream effectors such as CCND1 (cyclin D1), BCL2, matrix metalloproteinases, and other cell cycle regulators. Additionally, BLZF1 interfaces with p53 and SMAD2/3 signaling nodes to govern cellular decisions between proliferation, differentiation, and apoptosis.
The combination of BLZF1 knockout and the HAP1 haploid background creates a compelling model for dissecting gene function in cancer-related contexts. Loss of BLZF1 impairs the transcription of proliferation- and survival-associated genes, leading to reduced cell growth and enhanced susceptibility to apoptotic stimuli. In HAP1 cells, the haploid state ensures that the knockout phenotype is not masked by a second functional allele, providing clear-cut genotype-phenotype correlations. This system is well-suited for investigating how BLZF1 mediates resistance to chemotherapeutic agents or for identifying synthetic lethal interactions with other oncogenic drivers. Researchers can exploit the polyclonal nature to study population-level responses, making it a valuable tool for drug sensitivity profiling and pooled CRISPR screens.
This product is designed for a broad range of research applications, including functional characterization of BLZF1 in glioma, acute myeloid leukemia, and other malignancies. Typical experimental approaches include western blotting and RT-qPCR to confirm target gene disruption, MTT proliferation and Annexin V apoptosis assays to assess phenotypic consequences, RNA-seq for transcriptomic profiling, and drug sensitivity assays to evaluate response to pathway inhibitors. The polyclonal knockout cells also enable haploid genetic interaction studies, where the impact of BLZF1 loss can be combined with other mutations or drug treatments. For further information on lot-specific performance and handling, please contact Ascent Research.
